| Jehangir Badar, MD | |
|
295 Varnum Ave, Lowell, MA 01854-2134 | |
| (978) 937-6439 | |
| Not Available |
| Full Name | Jehangir Badar |
|---|---|
| Gender | Male |
| Speciality | Surgery - Surgical Critical Care |
| Location | 295 Varnum Ave, Lowell, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114127420 | NPI | - | NPPES |
| 102758421 | Medicaid | PA |
| Entity Name | Allegheny Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073081493 PECOS PAC ID: 5395649586 Enrollment ID: O20040310000602 |
News Archive
A team of Italian investigators has discovered a new variant of an emerging antibiotic resistance mechanism. The new variant, dubbed mcr-1.2, confers resistance to colistin, a last-resort antibiotic against multidrug-resistant Gram-negative pathogens.
New research on contraceptive prevalence and unmet need for contraception in married or co-habiting women of reproductive age (15 – 49 years), based on data from 194 countries, suggests that although the proportion of women in this group using contraception has risen in the last two decades, and unmet need has fallen, 233 million married or co-habiting women are projected to have an unmet need for modern contraceptive methods by 2015.
Orexo AB and Boehringer Ingelheim announced today that Boehringer Ingelheim has selected a development candidate resulting from the worldwide exclusive research, development and commercialisation agreement which Boehringer Ingelheim had signed in November 2005 with Biolipox, a Swedish research-based pharmaceutical company acquired by Orexo in October 2007.
Nearly 50 lawmakers in Congress have spouses who work in the health care industry and that may be influencing their thinking on health reform, CQ Politics reports.
Idera Pharmaceuticals today announced that 48% of patients with moderate-to-severe plaque psoriasis (12 of 25) treated with IMO-3100, a selective antagonist of Toll-like Receptors (TLRs) 7 and 9, demonstrated improvements in Psoriasis Area Severity Index (PASI) scores of 35% to 90% from baseline at the completion of a randomized, double-blind, placebo-controlled Phase 2a clinical trial of two dose levels of IMO-3100 administered for four weeks, with a four-week follow-up period.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jehangir Badar, MD 47 High Street, Suite 101, North Andover, MA 01845 Ph: (978) 258-4734 | Jehangir Badar, MD 295 Varnum Ave, Lowell, MA 01854-2134 Ph: (978) 937-6439 |
News Archive
A team of Italian investigators has discovered a new variant of an emerging antibiotic resistance mechanism. The new variant, dubbed mcr-1.2, confers resistance to colistin, a last-resort antibiotic against multidrug-resistant Gram-negative pathogens.
New research on contraceptive prevalence and unmet need for contraception in married or co-habiting women of reproductive age (15 – 49 years), based on data from 194 countries, suggests that although the proportion of women in this group using contraception has risen in the last two decades, and unmet need has fallen, 233 million married or co-habiting women are projected to have an unmet need for modern contraceptive methods by 2015.
Orexo AB and Boehringer Ingelheim announced today that Boehringer Ingelheim has selected a development candidate resulting from the worldwide exclusive research, development and commercialisation agreement which Boehringer Ingelheim had signed in November 2005 with Biolipox, a Swedish research-based pharmaceutical company acquired by Orexo in October 2007.
Nearly 50 lawmakers in Congress have spouses who work in the health care industry and that may be influencing their thinking on health reform, CQ Politics reports.
Idera Pharmaceuticals today announced that 48% of patients with moderate-to-severe plaque psoriasis (12 of 25) treated with IMO-3100, a selective antagonist of Toll-like Receptors (TLRs) 7 and 9, demonstrated improvements in Psoriasis Area Severity Index (PASI) scores of 35% to 90% from baseline at the completion of a randomized, double-blind, placebo-controlled Phase 2a clinical trial of two dose levels of IMO-3100 administered for four weeks, with a four-week follow-up period.
› Verified 2 days ago
Suman Bhushan Koganti, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 275 Varnum Ave Ste 203, Lowell, MA 01854 Phone: 978-458-4300 | |
Richard J Rohrer, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 275 Varnum Ave Ste 203, Lowell, MA 01854 Phone: 978-458-4300 Fax: 978-458-4311 | |
Lerna Ozcan, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 275 Varnum Ave Ste 203, Lowell, MA 01854 Phone: 978-458-4300 Fax: 978-458-4311 | |
Wassim Mazraany, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 275 Varnum Ave Ste 203, Lowell, MA 01854 Phone: 978-458-4300 Fax: 978-458-4311 | |
Jana Simonds, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 275 Varnum Ave Ste 203, Lowell, MA 01854 Phone: 978-458-4300 | |
Dr. Michael E Jiser, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 275 Varnum Ave Ste 203, Lowell, MA 01854 Phone: 978-458-4300 Fax: 978-458-4311 |